-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
So far, a number of multinational pharmaceutical companies have announced their 2021 Chinese market performance
.
Eight multinational pharmaceutical companies including Roche, AstraZeneca, Bayer, Merck, Sanofi, Novartis, Novo Nordisk and Eli Lilly have achieved good growth in the Chinese market as a whole
.
Among them, Sanofi rebounded from a negative growth of -7.
7% in 2020 to 7.
9% in 2021
.
Merck grew by 60%
.
Data shows that Roche's total revenue in 2021 will be US$69.
012 billion, an increase of 9.
3%, of which revenue in China will be US$6.
27 billion, an increase of 12.
8%
.
AstraZeneca's total revenue was US$37.
417 billion, an increase of 41%, of which revenue in China was US$6.
011 billion, an increase of 12%
.
Bayer's total revenue was US$52.
015 billion, an increase of 6.
5%, of which revenue in China was US$4.
55 billion, an increase of 10.
7%
.
Merck's total revenue was US$48.
704 billion, an increase of 17%, of which revenue in China was US$4.
262 billion, an increase of 60%
.
Sanofi's total revenue was US$44.
556 billion, an increase of 7.
1%, of which revenue in China was US$3.
21 billion, an increase of 7.
9%
.
Novartis' total revenue was US$51.
626 billion, an increase of 6%, of which revenue in China was US$3.
052 billion, an increase of 18%
.
Novo Nordisk's total revenue was US$22.
385 billion, an increase of 11%, of which revenue in China was US$2.
547 billion, an increase of 14%
.
Lilly's total revenue was US$28.
318 billion, an increase of 15%, of which revenue in China was US$1.
661 billion, an increase of 49%
.
Overall, Chinese revenue remains a core driver of global growth for multinational pharmaceutical companies
.
For example, according to the data, AstraZeneca is a multinational pharmaceutical company with a high proportion of Chinese revenue in global revenue, accounting for 16.
06%, followed by Novo Nordisk accounting for 11.
38% and Roche accounting for 9%
.
It is understood that Sanofi’s performance in China has also returned to positive growth, mainly due to the promotion of Dupixent (duprilumab), Plavix (clopidogrel) and vaccines
.
Dupixent will become Sanofi's new mainstay as competition from Plavix generics intensifies
.
In addition, the inclusion of PCSK9 inhibitor Praluent (alicilumab) in the new medical insurance catalogue will also be a strong support for Sanofi's performance growth in China
.
Merck's cervical cancer vaccine Gardasil / Gardasil 9 is in short supply in China, providing cash flow for its expansion and strengthening of its pipeline of products under development
.
The author has learned that many multinational pharmaceutical companies have recently announced new developments in China
.
For example, Johnson & Johnson China Personal Health Care and Tencent jointly announced that they have reached a comprehensive strategic partnership.
The two parties will leverage their respective advantages to jointly explore in terms of disease education, product development, content co-creation, and digital innovation, and use technology as the driving force to accelerate personal health.
Digital capacity building and transformation in the field of nursing, upgrading user experience, helping more Chinese patients and consumers to enjoy the health management life>
.
Another example is the official launch of GlaxoSmithKline's "New Breath" project
.
It is reported that in order to further strengthen the prevention and treatment of chronic respiratory diseases and promote the improvement of standardized diagnosis and treatment of asthma in China, the First Affiliated Hospital of Guangzhou Medical University, the Guangzhou Institute of Respiratory Health and the National Center for Respiratory Medicine took the lead, GlaxoSmithKline China (GSK) ) supported the "New Breath" Chinese Asthma Patient Online Registration Database System Construction Project at the First Affiliated Hospital of Guangzhou Medical University, and held a signing ceremony for the second phase of the project
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Eight multinational pharmaceutical companies including Roche, AstraZeneca, Bayer, Merck, Sanofi, Novartis, Novo Nordisk and Eli Lilly have achieved good growth in the Chinese market as a whole
.
Among them, Sanofi rebounded from a negative growth of -7.
7% in 2020 to 7.
9% in 2021
.
Merck grew by 60%
.
Data shows that Roche's total revenue in 2021 will be US$69.
012 billion, an increase of 9.
3%, of which revenue in China will be US$6.
27 billion, an increase of 12.
8%
.
AstraZeneca's total revenue was US$37.
417 billion, an increase of 41%, of which revenue in China was US$6.
011 billion, an increase of 12%
.
Bayer's total revenue was US$52.
015 billion, an increase of 6.
5%, of which revenue in China was US$4.
55 billion, an increase of 10.
7%
.
Merck's total revenue was US$48.
704 billion, an increase of 17%, of which revenue in China was US$4.
262 billion, an increase of 60%
.
Sanofi's total revenue was US$44.
556 billion, an increase of 7.
1%, of which revenue in China was US$3.
21 billion, an increase of 7.
9%
.
Novartis' total revenue was US$51.
626 billion, an increase of 6%, of which revenue in China was US$3.
052 billion, an increase of 18%
.
Novo Nordisk's total revenue was US$22.
385 billion, an increase of 11%, of which revenue in China was US$2.
547 billion, an increase of 14%
.
Lilly's total revenue was US$28.
318 billion, an increase of 15%, of which revenue in China was US$1.
661 billion, an increase of 49%
.
Overall, Chinese revenue remains a core driver of global growth for multinational pharmaceutical companies
.
For example, according to the data, AstraZeneca is a multinational pharmaceutical company with a high proportion of Chinese revenue in global revenue, accounting for 16.
06%, followed by Novo Nordisk accounting for 11.
38% and Roche accounting for 9%
.
It is understood that Sanofi’s performance in China has also returned to positive growth, mainly due to the promotion of Dupixent (duprilumab), Plavix (clopidogrel) and vaccines
.
Dupixent will become Sanofi's new mainstay as competition from Plavix generics intensifies
.
In addition, the inclusion of PCSK9 inhibitor Praluent (alicilumab) in the new medical insurance catalogue will also be a strong support for Sanofi's performance growth in China
.
Merck's cervical cancer vaccine Gardasil / Gardasil 9 is in short supply in China, providing cash flow for its expansion and strengthening of its pipeline of products under development
.
The author has learned that many multinational pharmaceutical companies have recently announced new developments in China
.
For example, Johnson & Johnson China Personal Health Care and Tencent jointly announced that they have reached a comprehensive strategic partnership.
The two parties will leverage their respective advantages to jointly explore in terms of disease education, product development, content co-creation, and digital innovation, and use technology as the driving force to accelerate personal health.
Digital capacity building and transformation in the field of nursing, upgrading user experience, helping more Chinese patients and consumers to enjoy the health management life>
.
Another example is the official launch of GlaxoSmithKline's "New Breath" project
.
It is reported that in order to further strengthen the prevention and treatment of chronic respiratory diseases and promote the improvement of standardized diagnosis and treatment of asthma in China, the First Affiliated Hospital of Guangzhou Medical University, the Guangzhou Institute of Respiratory Health and the National Center for Respiratory Medicine took the lead, GlaxoSmithKline China (GSK) ) supported the "New Breath" Chinese Asthma Patient Online Registration Database System Construction Project at the First Affiliated Hospital of Guangzhou Medical University, and held a signing ceremony for the second phase of the project
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
